This exploratory study determined levels and reference ranges of 10 biomarkers potentially associated with aPAP (Table 5) to monitor the disease development in pulmonary alveolar proteinosis, including in patients treated with anti-GM-CSF antibodies. The gene discussed is CSF2; the disease is pulmonary alveolar proteinosis.